Arctic Bioscience AS (OB: ABS)
Health Care · Biotechnology · NO
Nkr2.86
-4.67% today · -28.6% 1Y
Arctic Bioscience AS (OB: ABS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.57M and employs 19 people.
Over the last twelve months the share price has lost 28.6%, trading between 2.51 and 4.65.
Tweenvest scores Arctic Bioscience AS across four factors: quality 26/100, value 64/100, growth 64/100. Its strongest factor is value.
ABS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.57M
- Revenue (TTM)
- $4.23M
- P/E
- —
- EPS
- -1.52
- Dividend yield
- —
- Beta (5Y)
- 1.07
- 52-week high
- Nkr4.65
- 52-week low
- Nkr2.51
- Avg volume (3M)
- —
- Shares outstanding
- 26.96M
- Employees
- 19
- Next earnings
- —
About Arctic Bioscience AS
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.
- ISIN
- NO0010859580
- Founded
- 2011
- Listed since
- Feb 24, 2021
- Exchange
- Oslo Bors
- Currency
- NOK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.18 | +0.63% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.43 | +0.13% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.80 | +0.72% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $554.22 | +1.21% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $835.53 | +0.85% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.58 | +13.46% |
Figures last refreshed Aug 18, 2026.